iparomlimab + tuvonralimab + platinum-based doublet chemotherapy

This combination therapy is a neoadjuvant regimen being evaluated for the treatment of resectable stage II-IIIB non-small cell lung cancer (NSCLC). It consists of QL1706, a bifunctional MabPair biologic product developed by Qilu Pharmaceutical, which contains two monoclonal antibodies: iparomlimab, an anti-PD-1 IgG4 antibody, and tuvonralimab, an anti-CTLA-4 IgG1 antibody. This dual immunotherapy approach is combined with standard-of-care platinum-based doublet chemotherapy. By simultaneously blocking the PD-1 and CTLA-4 immune checkpoints while inducing cytotoxic DNA damage through chemotherapy, the regimen aims to enhance anti-tumor immune responses and improve pathological response rates prior to surgical resection.

Brand names

Qiulei

Other names

QL1706 + chemotherapyIparomlimab and Tuvonralimab + Chemo